ClearPoint Neuro, Inc. (CLPT) reported $12.13 million in revenue for the quarter ended March 2026, representing a year-over-year increase of 43%. EPS of -$0.32 for the same period compares to -$0.22 a year ago.
The reported revenue represents a surprise of -1% over the Zacks Consensus Estimate of $12.25 million. With the consensus EPS estimate being -$0.28, the EPS surprise was -16.36%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how ClearPoint Neuro performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenue- Neurosurgery navigation and therapy: $5.9 million compared to the $6 million average estimate based on two analysts. The reported number represents a change of +78.8% year over year. Revenue- Capital equipment and software: $1.4 million compared to the $0.9 million average estimate based on two analysts. The reported number represents a change of +180% year over year. Revenue- Biologics and drug delivery: $4.8 million versus $5.4 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +2.1% change.View all Key Company Metrics for ClearPoint Neuro here>>>
Shares of ClearPoint Neuro have returned +21.8% over the past month versus the Zacks S&P 500 composite's +8.6% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ClearPoint Neuro, Inc. (CLPT): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).